ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 746

Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides

Joanna Robson1, Helen Doll2, Ravi Suppiah3, Oliver Flossmann4, Lorraine Harper5, Peter Hoglund6, David Jayne7, Alfred Mahr8, Kerstin Westman9 and Raashid A. Luqmani10, 1Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 2Department of Population Health, University of East Anglia, Norwich, United Kingdom, 3Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 4Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, 5Nephrology, University of Birmingham, Birmingham, United Kingdom, 6Competence Centre fo Clinical Research, Skane University Hospital, Lund, Sweden, 7Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 8Department of Internal Medicine, Hospital Saint-Louis, Paris, France, 9Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, 10Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, glucocorticoids, morbidity and mortality, outcome measures and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Granulomatosis with polyangiitis [Wegener’s] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI). Long term (up to 7 years) damage has been described for patients from four European Vasculitis Study Group (EUVAS) trials. The objective of this study is to determine the factors associated with long-term damage in the ANCA-associated vasculitides.

Methods: Data from N=535 patients from four EUVAS trials were studied. A long-term follow up (LTFU) questionnaire at 7 years post diagnosis was completed including VDI and glucocorticoid data. The associations between baseline (age, creatinine and BVAS scores) and follow-up data (number of relapses and duration of glucocorticoids) and damage over LTFU (total VDI scores and individual treatment related damage items) were explored. Multiple regressions were used to look for independent associations between baseline measures, cumulative factors and VDI scores at LTFU.

Results: 296 patients had steroid use and VDI data available at LTFU, with the mean length of use 40.4 (SD 16.7) months. On multiple linear regression, high levels of damage were associated with age at baseline (p=.048), serum creatinine (p=.042), number of relapses (p=.021), and cumulative glucocorticoid use (p=.026). Patients with a longer duration of glucocorticoid treatment [OR=1.21 per 10 months (95%CI 1.3 to 1.42), p=0.019] were more likely to have a total VDI score of ≥5 at LTFU.

Conclusion: Long term damage in the ANCA-associated vasculitides may be predicted by severity of initial disease, age, number of relapses and duration of steroids used; improvement in immunosuppressant therapies is therefore indicated.


Disclosure:

J. Robson,

GlaxoSmithKline,

5,

Nordic Pharma,

8;

H. Doll,
None;

R. Suppiah,
None;

O. Flossmann,
None;

L. Harper,
None;

P. Hoglund,
None;

D. Jayne,

Roche Pharmaceuticals,

2,

Genetech,

2,

Mitshubishi,

5,

Takeda,

5,

Roche Pharmaceuticals,

5,

Roche Pharmaceuticals,

8;

A. Mahr,

Laboratoire Francais de Biotechnologie,

9;

K. Westman,
None;

R. A. Luqmani,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/glucocorticoid-treatment-and-damage-in-the-antineutrophil-cytoplasm-antibody-associated-vasculitides/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology